UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1081 - 1093
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Survival Rate | Lymphoma, Non-Hodgkin - pathology | Neoplasm Recurrence, Local - pathology | Rituximab - administration & dosage | Bendamustine Hydrochloride - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Female | Aged | Neoplasm Staging | Drug Resistance, Neoplasm - drug effects | Lymphoma, Non-Hodgkin - drug therapy | Antimitotic agents | Monoclonal antibodies | Care and treatment | Lymphomas | Product development | Antineoplastic agents | Analysis | Index Medicus | Life Sciences | Cancer
Journal Article
The Lancet. Haematology, ISSN 2352-3026, 2017, Volume 4, Issue 4, pp. e176 - e182
Journal Article
Academic radiology, ISSN 1076-6332, 2007, Volume 14, Issue 3, pp. 330 - 339
Radiology | FDG-PET | drug development | imaging biomarker | chemotherapy response | lymphoma | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Reproducibility of Results | Humans | Female | Fluorodeoxyglucose F18 | Male | Positron-Emission Tomography | Lymphoma, Non-Hodgkin - diagnostic imaging | Quality Assurance, Health Care | Clinical Trials, Phase II as Topic | Lymphoma, Non-Hodgkin - drug therapy | Care and treatment | PET imaging | Conferences, meetings and seminars | Medicare | Leukemia | Development and progression | Cancer | Index Medicus
Journal Article
Best practice & research. Clinical haematology, ISSN 1521-6926, 2010, Volume 23, Issue 1, pp. 133 - 143
Hematology, Oncology and Palliative Medicine | chemoimmunotherapy | alemtuzumab | monoclonal antibody | ofatumumab | rituximab | Life Sciences & Biomedicine | Hematology | Science & Technology | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Humans | Antimitotic agents | Chemotherapy | Immunoglobulin E | Monoclonal antibodies | Antineoplastic agents | Biopharmaceutics | Cancer | Index Medicus
Journal Article
The Radiologic clinics of North America, ISSN 0033-8389, 03/2008, Volume 46, Issue 2, pp. 213 - 223
Non-Hodgkin lymphoma | Positron emission tomography scan | Hodgkin lymphoma | Response criteria | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Hodgkin Disease - diagnostic imaging | Hodgkin Disease - pathology | Humans | Tomography, X-Ray Computed | Clinical Trials as Topic | Lymphoma, Non-Hodgkin - diagnostic imaging | Positron-Emission Tomography - methods | Remission Induction | Disease Progression | Lymphoma, Non-Hodgkin - pathology | Lymphoma, Non-Hodgkin - therapy | Hodgkin Disease - therapy | Fluorodeoxyglucose F18 | Neoplasm Staging | Radiopharmaceuticals
Journal Article
Clinical lymphoma, myeloma and leukemia, ISSN 2152-2650, 2010, Volume 10, Issue 5, pp. 400 - 400
Journal Article
Clinical lymphoma, myeloma and leukemia, ISSN 2152-2650, 2010, Volume 10, Issue 4, pp. 303 - 304
Journal Article
Hematology/oncology clinics of North America, ISSN 0889-8588, 08/2019, Volume 33, Issue 4, p. 727
Journal Article
Clinical lymphoma, myeloma and leukemia, ISSN 2152-2650, 2010, Volume 10, Issue 5, pp. 323 - 330
Journal Article
Hematology/oncology clinics of North America, ISSN 0889-8588, 10/2007, Volume 21, Issue 5, pp. 841 - 854
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hodgkin Disease - pathology | Hodgkin Disease - therapy | Humans | Neoplasm Recurrence, Local | Treatment Outcome | Clinical Trials as Topic | Positron-Emission Tomography | Consensus Development Conferences as Topic | Remission Induction | Practice Guidelines as Topic
Journal Article
Clinical lymphoma, myeloma and leukemia, ISSN 2152-2650, 2010, Volume 10, Issue 1, pp. 11 - 20
Hematology, Oncology and Palliative Medicine | Cyclophosphamide - administration & dosage | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Murine-Derived | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisolone - administration & dosage | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Rituximab | Multiple Myeloma - drug therapy | Antibodies, Monoclonal - administration & dosage | Vincristine - administration & dosage | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Index Medicus
Journal Article
Seminars in oncology, ISSN 0093-7754, 12/2016, Volume 43, Issue 6, pp. 647 - 654
Chronic lymphocytic leukemia | PI3K | Indolent non-Hodgkin lymphoma | Idelalisib | Lymphoma | Leukemia | Life Sciences & Biomedicine | Oncology | Science & Technology | Phosphatidylinositol 3-Kinases - genetics | Humans | Leukemia, Lymphocytic, Chronic, B-Cell - etiology | B-Lymphocytes - physiology | Phosphatidylinositol 3-Kinases - physiology | Signal Transduction - physiology | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Lymphoma, Non-Hodgkin - drug therapy | Lymphoma, Non-Hodgkin - etiology
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 9, pp. 1544 - 1552
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Tumors | Thalidomide - adverse effects | Cytokines - metabolism | Humans | Amyloidosis - drug therapy | Antineoplastic Agents - therapeutic use | Thalidomide - pharmacology | Multiple Myeloma - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Randomized Controlled Trials as Topic | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multicenter Studies as Topic | Waldenstrom Macroglobulinemia - drug therapy | Cytokines - drug effects | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Lymphoma, Non-Hodgkin - metabolism | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Thalidomide - therapeutic use | Lymphoma, Non-Hodgkin - drug therapy | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 02/2007, Volume 25, Issue 5, pp. 579 - 586
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Hodgkin Disease - diagnostic imaging | Endpoint Determination - standards | Tomography, X-Ray Computed - standards | Hodgkin Disease - pathology | Humans | Image Interpretation, Computer-Assisted | Terminology as Topic | Treatment Outcome | Lymphoma, Non-Hodgkin - diagnostic imaging | Immunohistochemistry - standards | Lymphoma, Non-Hodgkin - pathology | Time Factors | Flow Cytometry - standards | Lymphoma, Non-Hodgkin - therapy | Hodgkin Disease - therapy | Positron-Emission Tomography - standards | Survival Analysis | Fluorodeoxyglucose F18 | Clinical Trials as Topic - methods | Clinical Trials as Topic - standards | Radiopharmaceuticals | Index Medicus
Journal Article